(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of -1.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Voyager Therapeutics's revenue in 2025 is $80,001,000.On average, 5 Wall Street analysts forecast VYGR's revenue for 2025 to be $5,019,078,743, with the lowest VYGR revenue forecast at $220,827,540, and the highest VYGR revenue forecast at $8,064,069,692. On average, 5 Wall Street analysts forecast VYGR's revenue for 2026 to be $4,767,445,761, with the lowest VYGR revenue forecast at $220,827,540, and the highest VYGR revenue forecast at $8,112,651,751.
In 2027, VYGR is forecast to generate $4,160,501,267 in revenue, with the lowest revenue forecast at $220,827,540 and the highest revenue forecast at $6,780,123,168.